Your Health, We Care
Ibrutinib is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Ibrutinib is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion.
Ibrutinib is indicated for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
Ibrutinib is indicated for the treatment of adult and pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.
from FDA，2024.05
Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor that was first···【more】
Release date：2026-03-12Recommended：153
Ibrutinib (Imbruvica) is an oral Bruton's tyrosine kinase (BTK) inhibitor us···【more】
Release date：2026-03-12Recommended：134
Ibrutinib is a small molecule that acts as a potent, irreversible inhibitor of B···【more】
Release date：2026-03-12Recommended：138
Ibrutinib (Imbruvica) is a type of medication called a kinase inhibitor, used to···【more】
Release date：2026-03-12Recommended：125
Ibrutinib for the treatment of Chronic Lymphatic Leukemia【more】
Release date：2026-01-05Recommended：168
LuciusVersionofIbrutinib:DosageandAdministration,Indications,PrecautionsIndicati···【more】
Release date：2025-12-18Recommended：197
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
